Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection

References

• BretscherPAA two-step, two-signal model for the primary activation of precursor helper T cellsProc Natl Acad Sci U S A19999611851909874793
   PubMed Web of Science ®Google Scholar
• HalloranPFImmunosuppressive drugs for kidney transplantationN Engl J Med2004351262715272915616206
   PubMed Web of Science ®Google Scholar
• LiXCRothsteinDMSayeghMHCostimulatory pathways in transplantation: challenges and new developmentsImmunol Rev2009229127129319426228
   PubMed Web of Science ®Google Scholar
• GreenwaldRJFreemanGJSharpeAHThe B7 family revisitedAnnu Rev Immunol20052351554815771580
   PubMed Web of Science ®Google Scholar
• BromleySKIaboniADavisSJThe immunological synapse and CD28-CD80 interactionsNat Immunol20012121159116611713465
   PubMed Web of Science ®Google Scholar
• AlegreMLFrauwirthKAThompsonCBT-cell regulation by CD28 and CTLA-4Nat Rev Immunol20011322022811905831
   PubMed Web of Science ®Google Scholar
• McAdamAJSchweitzerANSharpeAHThe role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cellsImmunol Rev19981652312479850864
   PubMed Web of Science ®Google Scholar
• SharpeAHAbbasAKT-cell costimulation – biology, therapeutic potential, and challengesN Engl J Med20063551097397516908487
   PubMed Web of Science ®Google Scholar
• GreeneJLLeytzeGMEmswilerJCovalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactionsJ Biol Chem19962714326762267718900156
   PubMed Web of Science ®Google Scholar
• SalomonBBluestoneJAComplexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantationAnnu Rev Immunol20011922525211244036
   PubMed Web of Science ®Google Scholar
• WalunasTLLenschowDJBakkerCYCTLA-4 can function as a negative regulator of T cell activationImmunity1994154054137882171
   PubMed Web of Science ®Google Scholar
• van KootenCBanchereauJFunctions of CD40 on B cells, dendritic cells and other cellsCurr Opin Immunol1997933303379203418
   PubMed Web of Science ®Google Scholar
• GrewalISFlavellRACD40 and CD154 in cell-mediated immunityAnnu Rev Immunol1998161111359597126
   PubMed Web of Science ®Google Scholar
• ShimizuKSchönbeckUMachFLibbyPMitchellRNHost CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosisJ Immunol200016563506351810975872
   PubMed Web of Science ®Google Scholar
• KawaiTAndrewsDColvinRBSachsDHCosimiABThromboembolic complications after treatment with monoclonal antibody against CD40 ligandNat Med200062114
   Web of Science ®Google Scholar
• FordMLLarsenCPTranslating costimulation blockade to the clinic: lessons learned from three pathwaysImmunol Rev2009229129430619426229
   PubMed Web of Science ®Google Scholar
• SchwartzRHT cell anergyAnnu Rev Immunol20032130533412471050
   PubMed Web of Science ®Google Scholar
• KirkADHarlanDMArmstrongNNCTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primatesProc Natl Acad Sci U S A19979416878987949238056
   PubMed Web of Science ®Google Scholar
• LenschowDJWalunasTLBluestoneJACD28/B7 system of T cell costimulationAnnu Rev Immunol1996142332588717514
   PubMed Web of Science ®Google Scholar
• LarsenCPElwoodETAlexanderDZLong-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathwaysNature199638165814344388632801
   PubMed Web of Science ®Google Scholar
• LarsenCPPearsonTCAdamsABRational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive propertiesAm J Transplant20055344345315707398
   PubMed Web of Science ®Google Scholar
• EmamaulleeJTosoCMeraniSShapiroAMCostimulatory blockade with belatacept in clinical and experimental transplantation – a reviewExpert Opin Biol Ther20099678979619426116
   PubMed Web of Science ®Google Scholar
• SakaguchiSSakaguchiNShimizuJImmunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation toleranceImmunol Rev2001182183211722621
   PubMed Web of Science ®Google Scholar
• BluestoneJALiuWYabuJMThe effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantationAm J Transplant20088102086209618828769
   PubMed Web of Science ®Google Scholar
• ZhouZShenJHongYKaulSPfisterMRoyATime-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipientsClin Pharmacol Ther201292225125722760001
   PubMed Web of Science ®Google Scholar
• VincentiFLarsenCDurrbachACostimulation blockade with belatacept in renal transplantationN Engl J Med2005353877078116120857
   PubMed Web of Science ®Google Scholar
• VincentiFBlanchoGDurrbachAFive-year safety and efficacy of belatacept in renal transplantationJ Am Soc Nephrol20102191587159620634298
   PubMed Web of Science ®Google Scholar
• LatekRFleenerCLamianVAssessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturationTransplantation200987692693319300198
   PubMed Web of Science ®Google Scholar
• VincentiFCharpentierBVanrenterghemYA phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)Am J Transplant201010353554620415897
   PubMed Web of Science ®Google Scholar
• AdamsABPearsonTCLarsenCPHeterologous immunity: an over-looked barrier to toleranceImmunol Rev200319614716014617203
   PubMed Web of Science ®Google Scholar
• ButteMJKeirMEPhamduyTBSharpeAHFreemanGJProgrammed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responsesImmunity200727111112217629517
   PubMed Web of Science ®Google Scholar
• PilatNSayeghMHWekerleTCostimulatory pathways in transplantationSemin Immunol201123429330321616680
   PubMed Web of Science ®Google Scholar
• DurrbachAPrestanaJMPearsonTA phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)Am J Transplant201010354755720415898
   PubMed Web of Science ®Google Scholar
• VanrenterghemYBresnahanBCampistolJBelatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)Transplantation201191997698321372756
   PubMed Web of Science ®Google Scholar
• LarsenCPGrinyóJMedina-PestanaJBelatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studiesTransplantation201090121528153521076381
   PubMed Web of Science ®Google Scholar
• FlormanSBeckerTBresnahanBThree-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT)Am J Transplant201111Suppl S228559 [Abstract 229]21476218
   PubMedGoogle Scholar
• SuVCHarrisonJRogersCEnsomMHBelatacept: a new biologic and its role in kidney transplantationAnn Pharmacother2012461576722215686
   PubMed Web of Science ®Google Scholar
• MartinSTTichyEMGabardiSBelatacept: a novel biologic for maintenance immunosuppression after renal transplantationPharmacotherapy201131439440721449628
   PubMed Web of Science ®Google Scholar
• FergusonRGrinyóJVincentiFImmunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipientsAm J Transplant2011111667621114656
   PubMed Web of Science ®Google Scholar
• ArchdeaconPDixonCBelenOAlbrechtRMeyerJSummary of the US FDA approval of belataceptAm J Transplant201212355456222335273
   PubMed Web of Science ®Google Scholar
• IppolitiGRinaldiMPellegriniCViganòMIncidence of cancer after immunosuppressive treatment for heart transplantationCrit Rev Oncol Hematol200556110111315979322
   PubMed Web of Science ®Google Scholar
• NULOJIX^® (belatacept) [package insert]Princeton, NJBristol-Myers Squibb2011 Available from: http://packageinserts.bms.com/pi/pi_nulojix.pdfAccessed August 23, 2012
   Google Scholar
• GrinyóJCharpentierBPestanaJMAn integrated safety profile analysis of belatacept in kidney transplant recipientsTransplantation201090121521152721088650
   PubMed Web of Science ®Google Scholar